目次

TABLE OF CONTENT

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 KEY INCLUSIONS & EXCLUSIONS
1.3 RESEARCH SCOPE
1.3.1 SEGMENTS COVERED
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 MAJOR MARKET STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA SOURCES
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.3 MARKET SHARE ESTIMATION METHODOLOGY
2.4 MARKET BREAK DOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 SCOPE RELATED LIMITATIONS
2.6.2 METHODOLOGY RELATED LIMITATIONS
2.7 RISK ASSESSMENT
2.8 RECESSION IMPACT ASSESSMENT APPROACH

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW
5.1 MARKET DYNAMICS
5.1.1 MAJOR DRIVERS
5.1.2 KEY RESTRAINTS
5.1.3 KEY GROWTH OPPORTUNITIES
5.1.4 INDUSTRY-SPECIFIC CHALLENGES
5.2 REGULATORY LANDSCAPE
5.2.1 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
5.2.2 REGULATORY TRENDS
5.3 VALUE CHAIN ANALYSIS
5.4 SUPPLY CHAIN ANALYSIS
5.5 ECOSYSTEM MARKET MAP
5.6 TECHNOLOGY MAP
5.7 TRADE DATA
5.8 PATENT DATA
5.9 REIMBURSEMENT SCENARIO
5.10 CASE STUDY ANALYSIS
5.11 PORTER’S FIVE FORCE ANALYSIS
5.12 PRICING ANALYSIS
5.12.1 AVERAGE SELLING PRICE OF KEY PLAYERS BY PRODUCT
5.12.2 AVERAGE SELLING PRICE TRENDS, BY REGION
5.13 KEY CONFERENCES AND EVENTS IN 2023-24
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
5.14..2 BUYING CRITERIA

6 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE (USD MILLION; 2021—2028)*
6.1 PRODUCTS
6.1.1 CYCLOTRONS
6.1.2 SYNCHROTRON
6.1.3 SYNCHROCYCLOTRONS
6.2 SERVICES

7 PARTICLE THERAPY MARKET, BY TYPE (USD MILLION; 2021—2028)*
7.1 PROTON THERAPY
7.2 HEAVY ION THERAPY

8 PARTICLE THERAPY MARKET, BY SYSTEM (USD MILLION; 2021—2028)*
8.1 MULTI-ROOM SYSTEMS
8.2 SINGLE-ROOM SYSTEMS

9 PARTICLE THERAPY MARKET, BY APPLICATION (USD MILLION; 2021—2028)*
9.1 TREATMENT APPLICATIONS
9.2 RESEARCH APPLICATIONS

10 PARTICLE THERAPY MARKET, BY CANCER TYPE (USD MILLION; 2021—2028)*
10.1 PEDIATRIC CANCER
10.2 PROSTATE CANCER
10.3 LUNG CANCER
10.4 BREAST CANCER
10.5 HEAD AND NECK CANCER
10.4 OTHER CANCER

11 PARTICLE THERAPY MARKET, BY REGION (USD MILLION; 2021—2028)*
11.1 NORTH AMERICA
11.1.1 RECESSION IMPACT
11.1.2 US
11.1.3 CANADA
11.2 EUROPE
11.2.1 RECESSION IMPACT
11.2.2 GERMANY
11.2.3 UK
11.2.4 FRANCE
11.2.5 ITALY
11.2.6 SPAIN
11.2.7 REST OF EUROPE
11.3 ASIA-PACIFIC
11.3.1 RECESSION IMPACT
11.3.2 JAPAN
11.3.3 CHINA
11.3.4 INDIA
11.3.5 SOUTH KOREA
11.3.6 AUSTRALIA
11.3.7 REST OF ASIA-PACIFIC
11.4 LATIN AMERICA
11.4.1 RECESSION IMPACT
11.4.2 BRAZIL
11.4.3 MEXICO
11.4.4 REST OF LATIN AMERICA
11.5 MIDDLE EAST AND AFRICA
11.5.1 RECESSION IMPACT

12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.3 REVENUE ANALYSIS OF KEY PLAYERS (2022)
12.4 MARKET SHARE ANALYSIS FOR TOP 5 GLOBAL PLAYERS (IN TERMS OF %REVENUE, IN 2022)
12.5 COMPANY EVALUATION MATRIX
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT
12.6 SME/START-UP EVALUATION MATRIX
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING
12.7 COMPETITIVE SITUATION AND TRENDS (2021-2023)
12.7.1 PRODUCT LAUNCHES
12.7.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
12.7.3 MERGERS & ACQUISITIONS
12.7.4 EXPANSIONS

13 COMPANY PROFILES**
(Business Overview, Products Offered, Industry-specific Developments for 2021-2023)***
13.1 KEY COMPANIES
13.1.1 VARIAN MEDICAL SYSTEMS,INC. (US)
13.1.2 MEVION MEDICAL SYSTEMS (US)
13.1.3 IBA WORLDWIDE(US)
13.1.4 SUMITOMO HEAVY INDUSTRIES LTD.(JAPAN).
13.1.5 BIOSIG TECHNOLOGIES, INC..
13.1.6 HITACHI, LTD.(JAPAN)
13.1.7 TOSHIBA MEDICAL SYSTEMS CORPORATION (JAPAN)
13.1.8 PROVISION HEALTHCARE, LLC (US )
13.1.9 OPTIVUS PROTON THERAPY INC. (US)..
13.1.10 PROTOM INTERNATIONAL(US)
13.1.11 ADVANCED ONCOTHERAPY (UK)
13.1.12 DANFYSIK A/S (Germany).
13.1.13 P-CUREA (US/ISRAEL).
13.1.14 ELKETA..
13.2 OTHER PLAYERS

14 APPENDIX